INTRODUCTION
TXA2 is an extremely potent but labile compound that is a key mediator in platelet secretion [1] . In resting platelets the biosynthesis of TXA2 is insignificant. However, when platelets are activated it is rapidly synthesized and released. The biosynthesis of TXA2 is a multistep process involving the release of arachidonic acid from membrane phospholipids, the oxygenation and cyclization of arachidonate to the prostaglandin endoperoxides (PGG2 and PGH2), and the rearrangement of the endoperoxides to form TXA2. Despite the efforts of a number of laboratories [2] [3] [4] , thromboxane synthase (which catalyses the synthesis of TXA2 from PGH2), has not been purified to homogeneity and is not well characterized. The present investigation was designed to investigate the effect of immobilizing thromboxane synthase in a lipophilic environment on the production of both TXA2 and HHT. To date it is still unclear whether TXA2 and HHT are both products of the reaction catalysed by thromboxane synthase, even though the formation of both TXA2 and HHT are inhibited to the same degree by a variety of inhibitors. Our results show that the enzymic conversion of PGH2 to both TXA2 and HHT is limited and that the enzyme is inactivated during TXA2 production.
EXPERIMENTAL Materials
Lubrol PX was purchased from Sigma Chemical Co. Arachidonic acid was obtained from Nu-Chek, Elysian, MN, U.S.A., and l-benzylimidazole from Aldrich Chemical Co. Prostaglandin standards, TXB2 and sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate (U-63,557A) were kindly supplied by the Upjohn Company, Kalamazoo, MI, U.S.A. Affi-Gel Blue was purchased from Bio-Rad Laboratories, DE-52 cellulose from Whatman, and Sephacryl S-300 and phenyl-Sepharose CL-4B from Pharmacia. [5,6,8,9,11,12,14,15- I To whom all correspondence and reprint requests should be addressed. potassium phosphate buffer, pH 7.4, containing 0.1 % Lubrol PX, 1 mM-EDTA, 10% (v/v) glycerol and 2.5 M-KCI. The eluted enzyme activity was then dialysed against the elution buffer minus the KCI. The dialysed enzyme preparation was either stored at -70°C or further purified by gel filtration using a Sephacryl S-300 column. Protein concentrations of enzyme samples were estimated by measuring their A280 and/or by the method of Bradford [5] .
Thromboxane synthase assay
Since TXA2 is extremely short-lived and is converted into TXB2 in aqueous medium, enzyme activities were assayed by measuring the formation of TXB2 immunoreactivity from PGH2. The reaction mixture contained 5 nmol of PGH2, enzyme fraction and 50 mm-potassium phosphate, pH 7.4, in a final volume of 1 ml. The reaction was initiated with PGH2 and allowed to proceed at 23°C for 3 min. The reaction was terminated by acidification with 0.025 ml of 2 M-HCI. The mixture was then neutralized and diluted for TXB2 measurement by radioimmunoassay.
Radioinmunoassay for TXB2
TXB2 immunoreactivity was by a sensitive and specific radioimmunoassay as described previously [6] . Each sample was run in duplicate at three dilutions and values were obtained within the linear portion of the standard curve. Antiserum against TXB2 was obtained by the repeated immunization of rabbits with TXB2 coupled to bovine serum albumin. The radioimmunoassay was performed by incubating 0.2 ml of TXB2 standards or samples with 0.1 ml of diluted antiserum (final resultant dilution of 1:5000) and 0.1 ml of 3H-labelled TXB2 (10000 c.p.m.). The incubation was carried out at room temperature for 1 h. Separation of the bound and free antigen was achieved using y-globulin-coated charcoal. The supernatant obtained after centrifugation was counted in a Packard liquid-scintillation counter. The bound: total ratio was calculated for each sample and the concentration of thromboxane B2 determined from a standard curve after logit transformation [7] . The antiserum showed little cross-reactivity with PGF2, (0.02%), PGE2 (0.02%), PGD2 (0.02%) or 6-oxoPGF1,, (0.01 % ). The sensitivity ofthe assay was 15 pg/200 ,ul (i.e. B/BO = 80%).
PGH2 synthesis and purification PGH2 was prepared using arachidonic acid and ram seminal vesicle microsomes as previously described [8, 9] . The biosynthetically produced PGH2 was purified over both a gravity flow silicic acid column and a cyanobonded phase h.p.l.c. self-packed column using a hexane/propan-2-ol gradient 110]. The identity and purity of the PGH2 was confirmed by NH3 direct chemical ionization mass spectrometry [11, 12] . The biological activity of purified PGH2 was assayed by its ability to aggregate human platelets. [1-14C]PGH2 (4.5 Ci/mol) was prepared as described above. During the synthesis and purification of PGH2 some HHT was also produced. The HHT was isolated by h.p.l.c. and identified by NH3 direct chemical ionization mass spectrometry also [12] . This HHT was used as a standard on the octadecyl (C18) reversed-phase h.p.l.c. column. Characterization of products formed from PGH2
Thromboxane synthase reaction supernatants were collected and acidified to pH 3.0. The acidified samples were loaded onto Sep-Pak C18 cartridges that had been prewashed with 5 ml of methanol and S ml of 0.5% aqueous acetic acid. After the sample had been added, the column was washed with S ml of 25% (v/v) methanol containing 0.5% acetic acid. Finally, the eicosanoid products were eluted with two 2 ml portions of90% (v/v) methanol containing 0.5% acetic acid. Table 1 represents a typical purification ofthromboxane synthase from human platelet microsomes. A 259-fold purification was obtained with a 17% recovery ofenzyme activity. The Mr of the enzyme was determined by measuring the elution volume of enzymic activity from a Sephacryl S-300 column equilibrated with 50 mMpotassium phosphate, pH 7.4, containing 0.1 % Lubrol PX, 1 mM-EDTA and 10% (v/v) glycerol. The Mr of the platelet thromboxane synthase was calculated to be The production of both TXB2 and HHT by the highly purified platelet enzyme was verified. In addition, the stability of these enzymic activities to increased temperatures was investigated. The temperature at which 50% of the enzymic activity remained (TO) after a 5 min incubation period was 51°C for TXB2 formation and 53°C for HHT formation (Fig. 1) . The T50 values for the platelet enzyme are very similar to those reported for the lung enzyme [13] .
Thromboxane synthase binds avidly to phenylSepharose CL-4B and cannot be washed off with 50 mM-potassium phosphate, pH 7.4, containing 0.2% Lubrol PX. Experiments conducted with the enzyme bound to phenyl-Sepharose have shown that the enzyme retains most (i.e. 75-90 % ) ofits activity when bound. The immobilized enzyme can be inactivated at pH 3.0 and inhibited with 1-benzylimidazole and sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate (U-63,557A), demonstrating that the measured biological activity was in fact enzymically mediated (Fig. 2) (Table 2) .
Thus the enzyme appears to be inactivated during TXB2 production. The inactivation of thromboxane synthase was dependent on the concentration of PGH2 used in relationship to the amount of enzyme present. For example when 6 /sg ofimmobilized enzyme was incubated with two additions of 5 nmol of PGH2, the second incubation of PGH2 produced 61 % less TXB2 than did 10 .2% in the third incubation (Fig. 3) . Apparently the enzyme is being inactivated during the conversion of PGH2 to TXB2 and HHT.
The inactivation of thromboxane synthase must occur by a different mechanism than that shown for the inactivation of prostaglandin endoperoxide synthase (cyclo-oxygenase). Cyclo-oxygenase is inactivated by free radicals generated during the peroxidative reduction of PGG2 to PGH2, which would be a most unlikely process for the thromboxane synthase since it was inactivated when purified PGH2' containing no PGG2, was used as substrate [14] . Ullrich and coworkers [15] have suggested that thromboxane synthase is a haemoprotein ofthe P-450 type; if true, the observed substrate inactivation of the enzyme may involve a modification of the haem group similar to that described for prostacyclin synthase [16] . If the enzyme's inactivation involves a modification of a haem at the active site, then our data would suggest that the haem participates in the production of both TXB2 and HHT. Another explanation ofthromboxane synthase inactivation might be the depletion of a required cofactor during the reaction. It is interesting to note that thromboxane synthase binds to an Affi-Gel Blue column, which is generally thought to have a biospecific affinity for nucleotide-requiring enzymes. However, we have been unable to elute thromboxane synthase from Affi-Gel Blue using up to 1 mm concentrations of NAD+, NADH, NADP+, NADPH, ATP or ADP. In addition, none of the compounds were capable ofreactivating thromboxane synthase activity lost during the incubation of the enzyme with PGH2. Although additional work is necessary to identify the mechanism of enzyme inactivation, this inactivation may well represent an important regulation in vivo of TXA2 production.
